

Connectyx's MedFlash Product will participate in a Personal Health Record study conducted by Harvard Medical School and Brigham and Women's Hospital.

Palm City, Florida, June 18, 2008. Connectyx Technologies Holdings Group, Inc. (OTCPK: CTYX) announced today that MedFlash will participate in a Personal Health Record study conducted by Brigham and Women's Hospital and Harvard Medical School. Ronn Schuman the company's CEO stated, "We were recently contacted by a research team that is reviewing the features and benefits of commercially available PHR's and welcomed the invitation to have our innovative product be part of their study." Adam Wright, a faculty member at Brigham and Women's Hospital and Harvard Medical School is one of the researchers leading the study stated, "Our goal is to learn what features devices on the market have, and how they work". Ronn Schuman the company's CEO stated "They expect the study to take several months and are looking toward a September publication date."

About Connectyx - MedFlash www.med-flash.com www.connectyx.com www.mrnmanager.com

Connectyx Technologies (OTCPK: CTYX) currently has two top tier Medical product divisions that are revolutionary in each business category – MedFlash and MRN Manager.

Both MedFlash™ and MRN Manager™ have broad appeal in their respective markets and are in the most sought after technology growth sectors: Personal health records and Revenue cycle management.

MedFlash is a Personal Health Record device and has no equal in the marketplace. MedFlash began as a simple 128MG flash drive with embedded software that enabled the owner to control their personal health information. The company has now developed a web based portal that will enable its owners not only to keep medical history but gives them the ability to download MRI's, X-rays, and a host of other medical and life style information all on a 1 GB flash drive that can plug into any computer and or be accessed directly from the Internet. MedFlash has experienced significant sales increases in the last 6 months due to a number of new customers. MedFlash has the price point that appeals to all age sectors and its distribution is not limited to the retail marketplace. MedFlash is being introduced to charitable organizations for fundraising efforts, has corporate logo appeal, can be sold via physicians practices, through insurance companies, given away as a corporate benefit, valuable to the travel industry for clients leaving the US, has the ability to be translated into many languages and the list goes on.

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from those anticipated. Such risks and uncertainties include, but are not limited to, rules and regulations promulgated under the Act, unanticipated changes in Medicare reimbursement, outcomes of government reviews, inquiries and investigations and related litigation, continued compliance with government regulations, fluctuations in customer demand, management of rapid growth, competition from other healthcare product vendors, timing and acceptance of new product introductions, general economic conditions, geopolitical events and regulatory changes, as well as other relevant risks. The information set forth herein should be read in light of such risks. Connectyx assumes no obligation to update the information contained in this press release.

INVESTOR CONTACT:

Mr. Greg Catinella
772-600-2581